Ozempic vs Saxenda
Side-by-side on efficacy, form, dosing, side effects, and 2026 cash-pay and insurance pricing.
| Ozempic | Saxenda | |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Form | Injection | Injection |
| Avg weight loss | ~10–14% | ~5–8% |
| Cash price / mo | $349/mo | $299/mo (generic) |
| FDA for obesity | Off-label | Approved |
Ozempic (semaglutide weekly) is a newer, more effective GLP-1 for type 2 diabetes with 8–14% weight loss as a secondary effect. Saxenda (liraglutide daily) was the first FDA-approved GLP-1 for weight loss and delivers 5–8%. Ozempic is the stronger diabetes drug; Saxenda's main advantage is generic availability and pediatric approval.
Who wins on what
Different drugs, different eras
Ozempic (semaglutide) launched in 2017 for type 2 diabetes. Saxenda (liraglutide) launched in 2014 for obesity. They share the GLP-1 mechanism but differ in molecular design, dosing frequency, and FDA indication.
For diabetes, Ozempic is the more effective choice. For adolescent weight management, Saxenda is the only approved GLP-1. For adult weight loss, neither is first-line in 2026 — Wegovy or Zepbound are.
Cost and access
Ozempic has broad insurance coverage for diabetes (commercial, Medicare, most Medicaid). Saxenda has moderate coverage for obesity and generic liraglutide is cheap on cash.
Frequently asked questions
Is Ozempic or Saxenda better for weight loss?
Ozempic produces more weight loss at maximum dose (~10–14%) than Saxenda (~5–8%). But for adult weight loss specifically, Wegovy (the semaglutide weight-loss dose) is the on-label choice; Saxenda is mostly reserved for pediatrics or generic-cost use cases.
Can I switch from Saxenda to Ozempic?
Yes, but the switch is usually done for diabetes control rather than weight loss — in which case Wegovy is the weight-focused alternative. Ask your prescriber about timing.
Not sure which is right for you? Take the Sherpa Matcher — it accounts for your goals, budget, and insurance in 60 seconds.